FDAapproval83% confidence
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Hikma.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Chemotherapy Support
- Sub-indication
- General
Related signal: Hikma's Leucovorin Calcium ANDA072733 Receives Abbreviated Approval